BANGKOK, October 24 (Asia Tech Wire) --The 37th Annual Conference of the International Papillomavirus Society (IPVS) kicked off in Bangkok on October 23, drawing over 1,000 researchers, clinicians, and industry representatives from around the world. Through exhibitions, seminars, and lectures, the conference highlighted the latest advances in papillomavirus research — including China’s independently developed HPV 9-valent vaccine, which stood out as a key highlight.
Xiamen Innovax Biotech Co., Ltd. (“Innovax”) hosted a symposium themed “A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination,” presenting the latest research progress of its independently developed HPV 9-valent vaccine, Cecolin 9, and its localized production in Thailand.
Professor Ting Wu from Xiamen University highlighted a study published in The Lancet Regional Health - Western Pacific in September 2025, which showed that Cecolin 9 demonstrated immunogenicity comparable to a marketed HPV 9-valent vaccine during both the peak and stable phases of the immune response. This finding, he added, indicates Cecolin 9 may have similar long-term immune protection potential.
Dr. Tiffany Jiang, General Manager of Wantai Group, attended the IPVS conference and emphasized that Wantai's continuous innovation contributes Chinese strength to the global cervical cancer elimination initiative. Thailand marks the first stop for Innovax’s overseas localization cooperation. Through technology transfer, Innovax is committed to supporting Thailand in achieving localized production of the HPV 9-valent vaccine, ensuring a robust and sustainable supply. Future efforts will continue to deepen cooperation with Thailand, providing Chinese solutions for public health in Thailand and globally.
Professor Youlin Qiao, Distinguished Professor at the Chinese Academy of Medical Sciences & Peking Union Medical College, and a member of the WHO Global Expert Group on Cervical Cancer Elimination, stated at the conference that China’s self-developed E. coli-based VLP vaccine technology platform offers a new solution for global vaccine research and development. He explained that the platform's high-efficiency expression advantage allows for the production of HPV vaccines that are actively supporting the goals of the WHO's Global Strategy to Accelerate the Elimination of Cervical Cancer.
Dr. Wichai Termrungruanglert, Vice President of the Royal Thai College of Obstetricians and Gynaecologists and Co-Chair of the 37th IPVS, noted in an interview that the Chinese HPV 9-valent vaccine provides strong support for Thailand’s cervical cancer elimination efforts. He affirmed that the localized production and technical expertise provided by Innovax are fundamental to securing a stable vaccine supply and realizing Thailand's goal of self-sufficiency.
Innovax has established a complete HPV vaccine production line based on its proprietary E. coli technology platform. In July 2024, Innovax signed a technology transfer agreement with Thailand's GBP for its HPV 9-valent vaccine, which will directly support the establishment of local HPV vaccine production capacity in Thailand. Thailand was also the first country to introduce Innovax’s bivalent HPV vaccine, Cecolin. As of October 2025, more than two million doses of Cecolin have been distributed in the Thai market.
The annual conference of IPVS is organized by the International Papillomavirus Society. Founded in 2000, the International Papillomavirus Society is a non-profit international organization composed of biomedical experts researching papillomaviruses and related diseases, dedicated to promoting the elimination of papillomavirus-associated diseases.
